2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Targeted Therapies
Targeted therapies revolutionize cancer treatment by precisely pinpointing and attacking cancer cells while sparing healthy tissues. Unlike conventional treatments like chemotherapy, which can harm both cancerous and healthy cells, targeted therapies focus on specific molecular alterations driving cancer growth. These therapies often involve drugs that interfere with proteins, genes, or pathways critical for cancer progression. Through advanced diagnostics like genetic testing, doctors can identify these specific targets, tailoring treatment to each patient's unique cancer profile. By honing in on the molecular vulnerabilities of tumors, targeted therapies offer greater efficacy with fewer side effects, marking a significant stride in personalized cancer care. As research delves deeper into understanding cancer biology, the promise of targeted therapies continues to expand, offering hope for more precise and effective treatments in the fight against cancer.
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China